Columbia University

Technology Ventures


Dan Goodman

Relativity Sciences, Lockheed Martin, University of Maryland EiR
Year Served: 
Dan Goodman is a serial entrepreneur, consultant, advisor and educator who has founded or co-founded 14 companies and three non-profit organizations since 1970. He has held leadership roles in several fields including industrial product development, technology commercialization, renewable energy, venture capital, and organizational development. 
Dan is the CEO of Relativity Sciences, Inc., a culture-change consulting and training firm he founded in 2008, focusing on intrapreneurship, innovation, and customer intimacy for Fortune 500 companies and government organizations. He has been an advisor and consultant to well over one hundred organizations, from startups to venture capital firms to Fortune 100’s on entrepreneurship/intrapreneurship, strategy, commercialization, and culture change, and is a frequent lecturer and trainer on these topics.
Dan serves as the Entrepreneur-in-Residence (EiR) and Senior Fellow for Executive Development at the University of Maryland’s Robert H. Smith School of Business. For six years he was the EiR for the university’s Division of Research, where he advised senior university leadership on innovation, entrepreneurship, and commercialization strategies. Prior to that he was the EiR Emeritus and Technology Commercialization Fellow at the Smith School, where he co-taught MBA entrepreneurship classes. Dan also served as Research Development Lead for the Lockheed Martin strategic relationship, the university’s largest corporate partnership, where he developed and managed research collaborations in medical informatics, genomics, secure wireless communications, cyber-psychology, and robotics. He is an alumnus and board member of the Electrical and Computer Engineering Department at UMD’s Clark School of Engineering. From 2002 to 2004, Dan was the EiR at the university’s Office of Technology Commercialization, where he developed licensing deals for the university’s intellectual property portfolio.
Among his roles in companies he has founded, Dan was Chairman and Managing Director of Zernike USA, the U.S. arm of Zernike Group, a Dutch venture capital and science park management firm; President and CEO of The Silverthorn Group, a product development firm specializing in building automation, transportation, medical and energy systems; CEO of Odexia, a university spinout company commercializing a novel micro-electromechanical sensor (MEMS) for national security applications; and Partner and chief architect of Brainchild Maryland, the State of Maryland’s public-private partnership to accelerate the creation of spinout companies from the intellectual property in the State’s university and federal lab systems, funded by the Maryland Department of Business and Economic Development.
Dan was appointed by the Governor of Maryland to the board of directors of the State’s clean energy economic development authority, where he served as vice chairman, treasurer and chairman of the finance committee. He chaired Maryland’s first clean energy business incubator, and has been a board director or advisory board member on over a dozen other boards of corporations, non-profits, venture capital firms and business incubators, including the Chesapeake Innovation Center, the nation’s first homeland security business incubator (sponsored by the National Security Agency). 
Dan is co-authoring the upcoming book Triumphant Teams, a best-practices guide for corporate R&D professionals collaborating with academic researchers, together with Jim Severson, former President of the Cornell Research Foundation and AUTM (The Association of University Technology Managers).

Linda Masat

Takeda Pharmaceuticals, XOMA
Year Served: 

Linda Masat has 18 years of experience in the discovery and development of Biologics within global biotechnology and biopharmaceutical companies. As a strategic leader at Takeda Pharmaceutical and XOMA Linda has built state of the art discovery and preclinical development infrastructures and assembled and led talented multidisciplinary team of scientists that discovered therapeutic-grade biologic molecules to over 60 targets across multiple therapeutic areas. Three programs led by Linda entered clinical development stage and more are in IND-enabling research activities. She was the inventor of XOMA’s Gevokizumab, an IL1b antibody that was licensed to Novartis in 2017. As member of executive teams Linda helped develop and support corporate strategies through in-house research as well as both in-licensing and out-licensing activities.

After leading Takeda’s global antibody discovery capability, Linda joined Takeda’s Center for External Innovation. In this role she identified and managed innovative therapeutic programs in collaboration with academic laboratories and early stage companies to bring novel drug concept to bear at Takeda. She also was the Takeda scientific leader in residence and Scientific Advisory Board member at the Tri-Institutional Therapeutic Discovery Institute in New York City, where she managed the Biologics collaboration between the two organizations. Here she enabled translation of early stage programs from Cornell University, Memorial Sloan Kettering Cancer Center and Rockefeller University, to first in class therapeutic antibodies.

Currently an independent consultant, Linda provides expertise in the area of biologics discovery and preclinical development, due diligence for novel targets concepts and novel technology platforms, primarily in the immunology and oncology therapeutic areas.

Linda received her Ph.D. in Biochemistry from the University of Urbino, Italy. She did her postdoctoral training at the department of Immunology and Microbiology of the University of California, San Francisco. Her industry career includes leadership positions at Takeda Pharmaceutical, XOMA and Abgenix (now Amgen).


James Pastoriza

TDF Ventures, J.P Morgan Communications, AT&T Ventures
Year Served: 

Jim joined TDF early in 2004 and is the Managing Partner at the Fund. He has more than two decades in the Communications and Technology sector initially in operating positions and the last 17 in venture capital. Before joining TDF Ventures, Jim was a Partner at J.P. Morgan Communications Partners at their Telecom, Media and Technology Fund in San Francisco, CA. Before JPMorgan, he was a Partner at AT&T Ventures. Jim has led investments in over 15 exits via acquisition or public offerings. Prior to venture capital, Jim held operational positions at AT&T and Lucent Technologies. 

At AT&T, Jim was the Product Manager for AT&T’s largest P&L, Consumer Long Distance Service. He also served as the Executive Assistant to AT&T’s Senior Vice President of Corporate Strategy and Development. Previously, Jim was a Lucent Technologies Account Executive ranking in the top 1% of national sales. He received a BSEE from Columbia University and is a member of their Engineering Advisory Board. 

Jim earned a Master of Science in Management from the Massachusetts Institute of Technology. 

David Pompliano

Area of expertise: 
Biopharmaceutical, medicine
Accelerator Life Science Partners, Lodo Therapeutics, Revolution Medicines
Year Served: 

David Pompliano is a drug discovery entrepreneur.  Working with venture-capitalists and academicians, He focuses on creating scientifically precocious, game-changing new commercial enterprises based on cutting edge science and technology discovered in academia.

Pompliano is an Operating Partner of Accelerator Life Science Partners.  With Accelerator LSP and Gates Foundation backing, Pompliano co-founded Lodo Therapeutics in 2015 with Professor Sean Brady (Rockefeller University), and served as its Chief Scientific Officer (CSO) until September 2018.  Lodo Therapeutics is a New York City-based company focused on metagenomics-based discovery and synthetic biological manipulation of novel secondary metabolite biosynthetic pathways to produce new medicines.  Pompliano continues to work with Accelerator to ideate and build new biotechnology companies.

Pompliano has over 25 years of experience in the biopharmaceutical industry.  Prior to Lodo Therapeutics, he served as CSO of Revolution Medicines, a drug discovery company he co-founded while an Entrepreneur in Residence at Third Rock Ventures.  Before that, he was CEO of BioLeap, a platform technology-based biopharma company. Earlier, he served as a senior pharmaceutical executive at GlaxoSmithKline and Merck, where he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and four registered anti-infective (Altabax) and oncology (Tykerb, Votrient, Promacta) drugs.  

Pompliano earned the BS and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles’ laboratory at Harvard University.  He also is Principal and Owner at Sanderling Consulting LLC, where he assists investors, companies and philanthropies in setting drug discovery strategy, in executing the operations of preclinical discovery and development, and in evaluating pharmaceutical assets.  He serves on the Scientific Advisory Boards of several biotechnology companies, government agencies and philanthropies.  He is also Chairman of Board of Directors for ABAC Therapeutics, an antibacterials development company in Barcelona.

Pompliano has published more than 50 peer-reviewed papers in the areas of infectious diseases and cancer drug discovery and mechanistic enzymology, and has presented over 50 invited lectures internationally. 

Pompliano played drums for Dr Quantum and the Operators, a group of Stanford chemistry graduate students who rocked with no uncertainty.




Lee Rauch

Area of expertise: 
Life Science Business Development
Fortress Biotech, Global Blood Therapeutics, Third Rock Venture
Year Served: 

Ms. Rauch is a Senior Executive and Business Advisor to public and venture backed life science companies with over 25 years of experience, including serving as CEO and in C-level positions. She is currently an Entrepreneur in Residence (EIR) at Fortress Biotech. As EIR, she identifies acquisition or investment opportunities through her relationships with leading scientists, physicians and founders at universities, early stage biotech companies and foreign pharma companies.  Previously, she was Chief Business Officer of Global Blood Therapeutics (GBT), a Third Rock Venture start up that is currently a multi-billion-dollar public company. At GBT, she helped grow the company from a few scientists doing molecular modeling to an integrated, multi-disciplinary organization with a potential block buster product in clinical development. Prior to GBT, Ms. Rauch was President and CEO of Nuon Therapeutics, a venture backed, clinical development stage company focused on inflammatory and rheumatic diseases. Ms. Rauch also held senior-level positions as Chief Business Officer at Onyx Pharmaceuticals (acquired by Amgen), SVP Corporate Development at COR Therapeutics (now part of Takeda) and Vice President of Strategic Marketing at Syntex (acquired by Hoffmann-La Roche).

Ms. Rauch’s consulting experience covers serving as managing director for Cervantes Life Science Partners and heading the Life Science Practice as a partner at the Mitchell Madison Group (acquired by US Web). She repositioned companies facing critical strategic and operational crossroads and executed successful business development, financing and M&A transactions. Her clients included Viralytics (acquired by Merck), Afferent Pharmaceuticals (acquired by Merck) and Stryker, where she worked on the multi-billion-dollar merger with Pfizer’s Howmedica Division. She was also a founding member of McKinsey & Company’s multinational pharmaceutical practice.

 Ms. Rauch is an active member of the Healthcare Business Women’s Association and a Springboard Enterprises Life Science Advisor. Previously, she was an expert advisor to several California Life Science Fellows All Star Team start-ups. Three of her companies have been funded and one is now public.  Ms. Rauch earned her undergraduate degree in chemistry from Arizona State University and her MBA degree from the University of Chicago.

Ms. Rauch has experience in several therapeutic areas including oncology, cardiovascular diseases, chronic cough, autoimmune diseases, CNS disorders and orphan drugs. She worked on the approved drugs Kyprolis®, Nexavar®, INTEGRILIN, CellCept®, Cytovene® and Aloxi®.


Edward Rosen

Glendevon Life Sciences Consulting, Elucida Oncology, J&J
Year Served: 

Ed Rosen is a serial entrepreneur with a foundation of success in multinational drug, device and diagnostic companies. Mr. Rosen is currently the founder and Principal of Glendevon Life Sciences Consulting LLC, supporting select market and technology assessment engagements and active in establishing new biotechnology companies.

Ed was the founding CEO, President, Chief Executive Officer and a Director of Elucida Oncology, Inc. and has a passion towards driving companies and the people within to fulfill their true potential. Over the last four years, he created the licensing, infrastructure, strategy and team for Elucida Oncology to thrive while attracting a world-class Board and achieving significant Series A financing.

Mr. Rosen has more than 20 years of operational and leadership experience in the life sciences industry. Prior to Elucida, he enjoyed a stellar career across a number of companies within Johnson & Johnson. As Worldwide Vice President of Marketing for a large surgical division, he developed an entirely new business model while overseeing the development of the leading direct to patient web presence in the industry. He co-led the re-birth of an immunology / oncology division setting it on a valuation journey from less than $100MM to $1.3Bn in five years. As Director of Health Economics and Reimbursement & Strategy for a large peripheral vascular division, Ed played an industry leading role in several national coverage determinations and developed a keen understanding of economic outcomes to add to his existing clinical trial design experience. As a marketer, he took a market-leading product suddenly and incorrectly facing an unheard-of level of attack from competition, regulators and clinicians and doubled revenue from the previous #1 market share position. Prior to Johnson & Johnson, Ed started his career with Smith & Nephew, plc, with roles in the United Kingdom and United States, including marketing, operations, technology transfer and sales.

Mr. Rosen holds a Bachelor of Arts with Honors in Business from the University of Lincoln in the United Kingdom.


Angela Shen

Area of expertise: 
Arcellx, NKarta Therapeutics, Cell Therapy Accelerator
Year Served: 

Dr. Angela Shen, M.D., M.B.A has extensive experience in clinical development, medical affairs, and business development, having led clinical programs in oncology in a variety of pharmaceutical settings. Angela is currently the Chief Medical Officer for Arcellx, Inc. and NKarta Therapeutics, and is the Founder of Cell Therapy Accelerator LLC which has provided clinical and strategic support for a number of immuno-oncology programs, including cell and gene therapy.

Angela previously served as Chief Medical Officer of Battersea Biotech and Arvinas, Inc. Angela spent over six years with Novartis Oncology. As a Global Clinical Program Head, she helped launch the CART-19 (CTL019; Kymriah) Cell & Gene Therapy program and built a clinical and operations team from the ground up. As Head of Clinical Evaluation for the Novartis Oncology Business Development group, she was extensively involved in licensing in new compounds to strengthen the Novartis oncology and hematology pipeline, including CTL019 (Kymriah) and SelG1 (Crizanlizumab). Previously, Angela was a Clinical Lead at Novartis for the development of new oncology assets including panobinostat (Farydak) and inhibitors of the enzyme PI3-kinase. At Exelixis, Angela served as Clinical Lead for multiple drugs in early development, including cobimetinib (Cotellic), which was subsequently developed by Genentech and obtained FDA approval. At Johnson & Johnson, she held a medical affairs role supporting Velcade, Doxil, Yondelis, and Procrit. Early in her career, Angela was a research fellow at NIH, and research assistant in the lab of Dr. Paul Lauterbur (2003 Nobel Prize Laureate). 

Angela received her MD from Albany Medical College in New York, followed by general surgery residency at Staten Island University Hospital, North Shore-LIJ Health System. She obtained her MBA, with a concentration in finance and management, from NYU Stern School of Business.